JZYY(600750) 新浪财经· Xin Lang Cai Jing·2025-05-12 04:34Core Viewpoint - In Q1 2025, the company reported a revenue of 1.184 billion yuan, a year-on-year decrease of 7.03%, while achieving a net profit attributable to shareholders of 285 million yuan, an increase of 5.91% [1] Group 1: Financial Performance - The company's Q1 2025 revenue breakdown includes 885 million yuan from the OTC segment (down 12.12% YoY), 187 million yuan from the prescription drug segment (up 23.68% YoY), and 111 million yuan from the health segment (up 0.59% YoY) [1] - The gross profit margin and net profit margin for Q1 2025 were 68.21% and 24.06%, respectively, reflecting increases of 1.20 percentage points and 2.94 percentage points YoY [1] Group 2: Cost Management - The company's expense ratios for sales, management, R&D, and financial costs in Q1 2025 were 33.80%, 4.51%, 2.28%, and -1.49%, showing changes of -1.79, +1.31, -0.07, and +0.20 percentage points YoY, respectively [2] Group 3: Future Outlook - The company is expected to achieve revenues of 4.9 billion yuan, 5.542 billion yuan, and 6.224 billion yuan from 2025 to 2027, with year-on-year growth rates of 10%, 13%, and 12% [2] - The projected net profits attributable to shareholders for the same period are 890 million yuan, 1.028 billion yuan, and 1.172 billion yuan, with growth rates of 13%, 16%, and 14% [2] - The company maintains a "buy" rating with projected PE valuations of 16, 14, and 12 times for 2025, 2026, and 2027, respectively [2]